Soligenix Inc. (SNGX)’s Financial Results Comparing With BioSpecifics Technologies Corp. (NASDAQ:BSTC)

Soligenix Inc. (NASDAQ:SNGX) and BioSpecifics Technologies Corp. (NASDAQ:BSTC) compete against each other in the Biotechnology sector. We will compare them and contrast their profitability, analyst recommendations, risk, institutional ownership, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Soligenix Inc. 5.52M 2.95 7.93M -0.83 0.00
BioSpecifics Technologies Corp. 29.81M 16.92 16.51M 2.40 29.63

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Soligenix Inc. and BioSpecifics Technologies Corp.

Profitability

Table 2 shows Soligenix Inc. and BioSpecifics Technologies Corp.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Soligenix Inc. -143.66% -142.4% -87%
BioSpecifics Technologies Corp. 55.38% 21.8% 20.7%

Volatility and Risk

Soligenix Inc. has a 1.31 beta, while its volatility is 31.00%, thus making it more volatile than S&P 500. Competitively, BioSpecifics Technologies Corp.’s beta is 1.29 which is 29.00% more volatile than S&P 500.

Liquidity

The Current Ratio of Soligenix Inc. is 3.3 while its Quick Ratio stands at 3.3. The Current Ratio of rival BioSpecifics Technologies Corp. is 48.4 and its Quick Ratio is has 48.4. BioSpecifics Technologies Corp. is better equipped to clear short and long-term obligations than Soligenix Inc.

Insider and Institutional Ownership

Roughly 23.1% of Soligenix Inc. shares are owned by institutional investors while 61.3% of BioSpecifics Technologies Corp. are owned by institutional investors. Insiders owned roughly 14.4% of Soligenix Inc.’s shares. On the other hand, insiders owned about 2.5% of BioSpecifics Technologies Corp.?s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Soligenix Inc. 2.2% 3.34% -17.7% -40% -54.41% 8.14%
BioSpecifics Technologies Corp. 2.61% 9.45% 20.32% 40.89% 78.69% 17.36%

For the past year Soligenix Inc. was less bullish than BioSpecifics Technologies Corp.

Summary

On 11 of the 11 factors BioSpecifics Technologies Corp. beats Soligenix Inc.

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates through two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase III clinical trial to treat cutaneous T-cell lymphoma; and proprietary formulations of oral beclomethasone 17,21-dipropionate for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. This segment also offers SGX942, an innate defense regulator technology that has completed Phase II clinical trial to treat oral mucositis in head and neck cancer. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase IB clinical trial for the treatment of vaccine against ricin toxin poisoning; VeloThrax, an anthrax vaccine candidate; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of melioidosis. Its vaccines are supported by its ThermoVax, a heat stabilization technology. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company offers injectable collagenase for the treatment of Dupuytren’s contracture and Peyronie’s disease under the XIAFLEX brand in Canada and Australia, as well as under XIAPEX brand name in Europe. It also provides injectable collagenase to treat frozen shoulder, cellulite, canine lipoma, lateral hip fat, and plantar fibromatosis, as well as for the treatment of human lipoma and uterine fibroids. The company is also involved in the development of other clinical indications for which collagenase injection has been tested, such as keloids, hypertrophic scars, scarred tendons, glaucoma, herniated intervertebral discs, and as an adjunct to vitrectomy. It has a development and license agreement with Endo Global Ventures. BioSpecifics Technologies Corp. was founded in 1957 and is headquartered in Lynbrook, New York.